CymaBay Therapeutics Inc. (CBAY)
(Delayed Data from NSDQ)
$13.12 USD
+0.67 (5.38%)
Updated May 3, 2019 04:00 PM ET
After-Market: $13.12 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.12 USD
+0.67 (5.38%)
Updated May 3, 2019 04:00 PM ET
After-Market: $13.12 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
CymaBay Therapeutics Inc. (CBAY) delivered earnings and revenue surprises of -9.38% and 85.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates
by Zacks Equity Research
Earnings from Biogen (BIIB) and CymaBay (CBAY) are in focus in the biotech sector.
Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline
by Zacks Equity Research
Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.
Company News for Feb 13, 2024
by Zacks Equity Research
Companies In The Article Are: FANG, JOBY,C, CBAY and GILD
Does CymaBay Therapeutics Inc. (CBAY) Have the Potential to Rally 45.99% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 46% in CymaBay Therapeutics Inc. (CBAY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are Medical Stocks Lagging Apyx Medical (APYX) This Year?
by Zacks Equity Research
Here is how Apyx Medical (APYX) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.
CymaBay Therapeutics Inc. (CBAY) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
CymaBay Therapeutics Inc. (CBAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
CymaBay (CBAY) Stock Up on Positive Results From PBC Study
by Zacks Equity Research
CymaBay (CBAY) reports encouraging data from the phase III study of seladelpar in PBC patients. Stock up.
Recent Price Trend in CymaBay Therapeutics Inc. (CBAY) is Your Friend, Here's Why
by Zacks Equity Research
CymaBay Therapeutics Inc. (CBAY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
CymaBay Therapeutics Inc. (CBAY) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
CymaBay Therapeutics Inc. (CBAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Here's Why Momentum in CymaBay Therapeutics Inc. (CBAY) Should Keep going
by Zacks Equity Research
CymaBay Therapeutics Inc. (CBAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
4 Best Breakout Stocks to Buy Now for Superlative Returns
by Tirthankar Chakraborty
CymaBay Therapeutics (CBAY), RxSight (RXST), UWM (UWMC) & Remitly Global (RELY) have been selected as the breakout stocks for today.
Wall Street Analysts Predict a 40.32% Upside in CymaBay Therapeutics Inc. (CBAY): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 40.3% upside potential for CymaBay Therapeutics Inc. (CBAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's What Could Help CymaBay Therapeutics Inc. (CBAY) Maintain Its Recent Price Strength
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, CymaBay Therapeutics Inc. (CBAY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Gilead Sciences (GILD) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.
Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Akero Therapeutics, Inc. (AKRO) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.
CymaBay Therapeutics Inc. (CBAY) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
CymaBay Therapeutics Inc. (CBAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Swedish Orphan Biovitrum (BIOVF) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Swedish Orphan Biovitrum (BIOVF) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.
CymaBay Therapeutics Inc. (CBAY) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
CymaBay Therapeutics Inc. (CBAY) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
CymaBay Therapeutics Inc. (CBAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CymaBay Therapeutics Inc. (CBAY) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
CymaBay Therapeutics Inc. (CBAY) delivered earnings and revenue surprises of -13.79% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for July 20th
by Zacks Equity Research
AEVA, BIDU, CBAY, DRNA and RACE have been added to the Zacks Rank #5 (Strong Sell) List on July 20, 2021.
5 Disruptive Biotech Stocks With Solid Long-Term Potential
by Kinjel Shah
Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.
Implied Volatility Surging for CymaBay Therapeutics (CBAY) Stock Options
by Zacks Equity Research
Investors need to pay close attention to CymaBay Therapeutics (CBAY) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in CymaBay (CBAY) Stock?
by Zacks Equity Research
Investors need to pay close attention to CymaBay (CBAY) stock based on the movements in the options market lately.